Login to Your Account



Investors Coy on New Isis-ApoCIIIRx Data

By Marie Powers
Staff Writer

Tuesday, July 23, 2013

After pushing shares of Isis Pharmaceuticals Inc. to a 52-week high in late June on the first Phase II data of antisense drug Isis-ApoCIIIRx, investors were more cautious Monday when the company reported additional Phase II data on patients with high to severely high triglycerides on stable doses of fibrates.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription